{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:06:33Z","timestamp":1786993593468,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.juro.2014.09.109","type":"journal-article","created":{"date-parts":[[2014,10,5]],"date-time":"2014-10-05T16:36:09Z","timestamp":1412526969000},"page":"1135-1143","source":"Crossref","is-referenced-by-count":79,"title":["Efficacy and Safety of MCNA in Patients with Nonmuscle Invasive Bladder Cancer at High Risk for Recurrence and Progression after Failed Treatment with bacillus Calmette-Gu\u00e9rin"],"prefix":"10.1097","volume":"193","author":[{"given":"Alvaro","family":"Morales","sequence":"first","affiliation":[{"name":"Queen\u2019s University, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Herr","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Steinberg","sequence":"additional","affiliation":[{"name":"University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Given","sequence":"additional","affiliation":[{"name":"Urology of Virginia, Virginia Beach, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvi","family":"Cohen","sequence":"additional","affiliation":[{"name":"Bioniche Therapeutics Corp., Pointe-Claire, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Amrhein","sequence":"additional","affiliation":[{"name":"Kingston and McDougall Scientific Ltd., Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[{"name":"University of Texas M.D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2014.09.109_bib1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","article-title":"The treated natural history of high risk superficial bladder cancer: 15-year outcome","volume":"158","author":"Cookson","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2014.09.109_bib2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","article-title":"Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review","volume":"60","author":"van den Bosch","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2014.09.109_bib3","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","article-title":"Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update","volume":"178","author":"Hall","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2014.09.109_bib4","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder: update 2013","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2014.09.109_bib5","doi-asserted-by":"crossref","first-page":"446","DOI":"10.6004\/jnccn.2013.0059","article-title":"Bladder cancer","volume":"11","author":"Clark","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.juro.2014.09.109_bib6","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2014.09.109_bib7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2014.09.109_bib8","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2006.01.017","article-title":"Management of BCG failures in superficial bladder cancer: a review","volume":"49","author":"Witjes","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2014.09.109_bib9","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1200\/JCO.2009.23.6901","article-title":"Bladder cancer: narrowing the gap between evidence and practice","volume":"27","author":"Hussain","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2014.09.109_bib10","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.urology.2007.01.040","article-title":"Volume, process of care, and operative mortality for cystectomy for bladder cancer","volume":"69","author":"Hollenbeck","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.juro.2014.09.109_bib11","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.eururo.2012.08.055","article-title":"Treatment options available for bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer","volume":"62","author":"Yates","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2014.09.109_bib12","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1517\/13543784.10.12.2157","article-title":"Therapeutic potential of mycobacterial cell wall-DNA complexes","volume":"10","author":"Filion","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.juro.2014.09.109_bib13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/sj.bjc.6690038","article-title":"Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells","volume":"79","author":"Filion","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.juro.2014.09.109_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s002620000121","article-title":"Modulation of\u00a0interleukin-12 synthesis by DNA lacking the CpG motif and present in a mycobacterial cell wall complex","volume":"49","author":"Filion","year":"2000","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.juro.2014.09.109_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/pros.1130","article-title":"Pro-apoptotic and immunomodulatory activity of a mycobacterial cell wall-DNA complex towards LNCaP prostate cancer cells","volume":"49","author":"Reader","year":"2001","journal-title":"Prostate"},{"key":"10.1016\/j.juro.2014.09.109_bib16","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/S0022-5347(05)65642-X","article-title":"Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder","volume":"166","author":"Morales","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2014.09.109_bib17","first-page":"1040","article-title":"Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed","volume":"181","author":"Morales","year":"2009","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.juro.2014.09.109_bib18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0022-5347(17)43959-0","article-title":"Risks\u00a0and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer","volume":"137","author":"Catalona","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2014.09.109_bib19","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2014.09.109_bib20","doi-asserted-by":"crossref","first-page":"E216","DOI":"10.1111\/j.1464-410X.2011.10894.x","article-title":"Prognostic significance of bacillus Calmette-Guerin failure classification in non-muscle-invasive bladder cancer","volume":"110","author":"Shirakawa","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2014.09.109_bib21","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0090-4295(97)00510-4","article-title":"Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Gu\u00e9rin","volume":"51","author":"Sarosdy","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.juro.2014.09.109_bib22","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","article-title":"Phase I trial of intravesical gemcitabine in bacillus Calmette-Gu\u00e9rin-refractory transitional cell carcinoma of the bladder","volume":"20","author":"Dalbagni","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2014.09.109_bib23","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","article-title":"Defining bacillus Calmette-Guerin refractory superficial bladder tumors","volume":"169","author":"Herr","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2014.09.109_bib24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00345-006-0112-0","article-title":"Treatment options\u00a0for BCG failures","volume":"24","author":"O\u2019Donnell","year":"2006","journal-title":"World J Urol"},{"key":"10.1016\/j.juro.2014.09.109_bib25","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2014.09.109_bib26","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","article-title":"SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Gu\u00e9rin","volume":"190","author":"Skinner","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2014.09.109_bib27","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.juro.2013.04.120","article-title":"Intravesical gemcitabine for high risk, nonmuscle\u00a0invasive bladder cancer after bacillus Calmette-Gu\u00e9rin treatment failure","volume":"190","author":"Sternberg","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2014.09.109_bib28","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a\u00a0randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2014.09.109_bib29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0302-2838(03)00371-3","article-title":"The side effects of bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"Sylvester","year":"2003","journal-title":"Eur Urol"},{"issue":"suppl.","key":"10.1016\/j.juro.2014.09.109_bib30","doi-asserted-by":"crossref","first-page":"e719","DOI":"10.1016\/j.juro.2012.02.1800","article-title":"Safety of intravesical mycobacterial cell wall-DNA complex given immediately postsurgery in patients with non-muscle-invasive bladder cancer","volume":"187","author":"Morales","year":"2012","journal-title":"J Urol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002253471404590X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002253471404590X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2014.09.109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T23:57:24Z","timestamp":1651190244000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2014.09.109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1016\/j.juro.2014.09.109"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2014.09.109","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}